RIGL
Rigel Pharmaceuticals Inc
47.10$
+1.0%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 97.7% | 97.9% | 97.5% | 98.6% | 98.5% | 80.6% | 80.6% | 92.3% | 86.3% | 84.7% | 82.4% | 46.8% | |
| 9.9% | 33.0% | 22.6% | 32.1% | 54.9% | 15.3% | 27.5% | 11.3% | 18.2% | 28.0% | 34.6% | 7.9% | |
| 92.9% | 95.8% | 95.7% | 97.2% | 92.4% | 66.5% | 51.9% | 74.7% | 43.3% | 48.6% | 47.2% | 30.2% | |
| 3.7% | 0.2% | – | – | 2.9% | 6.9% | 14.5% | 9.2% | 30.0% | 26.1% | 25.4% | 10.1% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.6% | 0.9% | 1.5% | 4.0% | 6.8% | 4.7% | 3.7% | 2.2% | |
| 1.6% | 1.2% | 1.5% | 0.7% | 1.0% | 1.5% | 2.4% | 7.1% | 0.6% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | 11.1% | 11.8% | 16.5% | 4.8% | |
| 16.8% | 30.6% | 29.6% | 15.5% | 21.0% | 63.5% | 69.2% | 81.8% | 110.1% | 124.4% | 98.0% | 23.8% | |
| 9.1% | 25.7% | 28.9% | 15.4% | 19.9% | 39.4% | 37.0% | 38.0% | 48.6% | 45.4% | 38.6% | 19.3% | |
| 1.8% | 2.3% | 4.1% | 0.2% | – | 4.9% | 7.8% | 5.9% | 0.8% | 6.8% | 4.6% | 5.9% | |
| 1.0% | 2.1% | 7.1% | 2.2% | 4.6% | 2.8% | 3.4% | 2.3% | 16.8% | 6.1% | 2.0% | 1.4% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | 6.6% | 18.0% | 11.9% | 29.4% | 44.7% | 32.0% | 4.4% | |
| 83.2% | 69.4% | 70.4% | 84.5% | 79.0% | 36.5% | 30.8% | 18.2% | -10.1% | -24.4% | 2.0% | 76.2% | |
| -610.0% | -752.7% | -1,357.7% | -956.1% | -869.3% | -864.8% | -1,183.2% | -791.2% | -1,029.5% | -1,200.7% | -847.7% | -199.2% | |
| 5.7% | 6.7% | 12.1% | 10.6% | 11.5% | 11.3% | 15.3% | 10.2% | 12.8% | 14.8% | 10.8% | 3.7% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.